bullish
Legend Biotech (LEGN.US) Offer Update - The Takeover Negotiations Could Reach an Impasse?
736 Views03 Sep 2024 08:55
Rumors swirl around acquisition price disagreement between Legend Bio and Genscrip. Deal has 50-50 chance of success. Investors still benefit if the deal breaks. Legend Bio remains high quality asset
What is covered in the Full Insight:
- Introduction
- Current Negotiation Status
- Impact on Legend Bio
- Impact on Genscript
- Future Outlook
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 3-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
Price Chart(Sign Up to Access)
- Pre-IPO Hangzhou Jiuyuan Gene Engineering (PHIP Updates) - The Future Prospects Are Not Optimistic19 Nov 2024
- Legend Biotech (LEGN.US) Offer Update - Will Deconsolidation Increase the Chances of a Merger ?13 Nov 2024
- Legend Biotech (LEGN.US) Offer Update - Is the Deal Really Dead?15 Oct 2024
- China TCM (570.HK) Privatization Update - Things Are Still Manageable06 Aug 2024
- Legend Biotech (LEGN.US) Offer Update - Some New Information About the Takeover Worth the Attention01 Aug 2024
- Legend Biotech (LEGN US) - A Takeover Offer?15 Jul 2024
x